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Simvastatin reverses the downregulation of M1/4 receptor binding in
6-hydroxydopamine-induced parkinsonian rats: the association with
improvements in long-term memory
Abstract
Background It is believed that muscarinic M1/4 receptors are closely correlated to the dopaminergic
system and are strongly involved in the pathogenesis of Parkinson's disease (PD). In addition to
regulating lipid metabolism and protection from stroke, statins have been used to regulate the declined
cognition. We aimed to explore the regional changes in M1/4 receptors in the 6-hydroxydopamine
(6-OHDA)-lesioned rat brain. Methods PD rat model was set up by injecting 6-OHDA into the unilateral
medial forebrain bundle; while simvastatin (10 mg/kg/day) or saline was orally administrated for 3 weeks,
respectively. Long-term memory was measured using the Morris water maze. [3H]pirenzepine binding
autoradiography was applied to investigate the alterations of M1/4 receptors in the PD rat brains. Results
6-OHDA induced long-term memory deficits along with downregulation of M1/4 receptors in the
hippocampus, the medial amygdala, the posteromedial cortical and the piriform cortex; simvastatin
administration significantly ameliorated the impaired memory and reversed the downregulation of M1/4
receptors in the examined brain regions. Profound positive correlations were verified between the decline
in long-term memory activity and the restoration of M1/4 receptors in different brain regions after
simvastatin treatment. Conclusions/significance Our results provide strong evidence that M1/4 receptor
modulation after simvastatin administration did, at least partially, contribute to the improvement in the
long-term memory in 6-OHDA-induced PD rats. These results provide a possible mechanism for
simvastatin treatment in psycho-neurological diseases such as PD via M1/4 receptors.
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Abstract
BACKGROUND: It is believed that muscarinic M1/4 receptors is closely correlated
to the dopaminergic system and are strongly involved in the pathogenesis of
Parkinson’s disease (PD). In addition to regulating lipid metabolism and protection
from stroke, statins have been used to regulate the declined cognition. We aimed to
explore the regional changes in M1/4 receptors in the 6-hydroxydopamine (6OHDA) lesioned rat brain. METHODS: PD rat model was set up by injecting 6OHDA into the unilateral medial forebrain bundle; while simvastatin (10mg/kg/day)
or saline was orally administrated for three weeks, respectively. Long-term memory
was

measured

using

the

Morris

water

maze.

[3H]pirenzepine

binding

autoradiography was applied to investigate the alterations of M1/4 receptors in the
PD rat brains. RESULTS: The 6-OHDA induced long-term memory deficits along
with downregulation of M1/4 receptors in the hippocampus, the medial amygdala,
the posteromedial cortical and the piriform cortex; simvastatin administration
significantly ameliorated the impaired memory and reversed the downregulation of
M1/4 receptors in the examined brain regions. Profound positive correlations were
verified between the decline in long-term memory activity and the restoration of
M1/4

receptors

in

different

brain

regions

after

simvastatin

treatment.

CONCLUSIONS/SIGNIFICANCE: Our results provide strong evidence that M1/4
receptor modulation after simvastatin administration did, at least partially, contribute
to the improvement in the long-term memory in 6-OHDA induced PD rats. These
results provide a possible mechanism for simvastatin treatment in psychoneurological diseases such as PD via M1/4 receptors.
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Highlights:
• 6-OHDA resulted in the impaired long-term memory in PD rats.
• Simvastatin ameliorated the impaired long-term memory in PD rats.
• 6-OHDA decreased M1/4 receptor binding in Hip, Me, PMCo, and Pir of PD
rat brains.
• Simvastatin reversed M1/4 receptor binding in the examined brain regions.
• The altered M1/4 receptor binding was related to the long-term memory in PD
rats.

Abbreviations:
ABC, avidin-biotin-peroxidase complex staining system;
Acb, accumbens nucleus;
AD, Alzheimer’s disease;
AI, agranular insular cortex;
Amy, amygdala;
ANOVA, analysis of variance;
AP: anteroposterior;
Arc, arcuate hypothalamic nucleus;
CA1: Cornu Ammonis area 1
Cg, cingulate cortex;
CPu, caudate putamen;
DAB, diaminobenzidine;
DMH, dorsomedial hypothalamic nucleus;
DPX, Di-N-Butyle Phthalate in Xylene;
DV, dorsoventral;
Ent, entorhinal cortex;
GPCR, G-protein-coupled receptors;
HEPES, 2-[4-(2-Hydroxyethyl)-1-piperazinyl]ethanesulfonic acid;
Hip, hippocampus;
HMG-CoA, hydroxymethylglutaryl-coenzyme A;
LDL, low-density lipoprotein;
LTP, long-term potentiation;
M1, primary motor cortex;
M1/4 receptor, muscarinic1/4 receptor;
Me, medial amygdala;
MFB, medial forebrain bundle;
ML, mediolateral;
MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine;
MWM, morris water maze;
NMDA, N-methyl-D-aspartic acid;
PBS, phosphate buffered saline;
Pir, piriform cortex;
PD, Parkinson’s disease;
PMCo, posteromedial cortical amygdala;
PRh, perirhinal cortex;
RSG, retrosplenial granular cortex;
SNpc, compact part of substantia nigra;
SNr, reticular part of substantia nigra;
TH, tyrosine hydroxylase;
Tha, thalamus;
Tu, olfactory tubercle ;
VDB, vertical limb of the diagonal band;
VMH, ventromedial hypothalamus;
VTA, ventral tegmental area;
6-OHDA, 6-hydroxydopamine.

Introduction
The cholinergic system and its neurodegeneration associated with Neurodegenerative
diseases such as Parkinson’s diseases (PD) and Alzheimer’s disease (AD) have
obtained considerable attention. Muscarinic receptors, one of the important elements
in the cholinergic system, have been widely explored. Muscarinic receptors are Gprotein-coupled receptors (GPCR) that include five subtypes M1–M5 (Bymaster et
al., 2003). Among these five subtypes, muscarinic M1 receptors that are localized to
the postsynaptic membrane are the most studied and abundant in the cerebral cortex,
the amygdala, the caudate putamen, and the hippocampus (Wang et al., 2008).
Increasing evidence indicates important roles for M1 receptors in learning and
functional memory regulation among the various neuropsychological disorders (Auld
et al., 2002; Hu et al., 2008; Digby et al., 2012). In aged rats with a decline in
memory and adult-onset cognitive dysfunction, the densities of M1 and M4 receptors
were profoundly decreased in brain regions including the Cornu Ammonis area 1
(CA1) and the frontal and occipital cortices (Tayebati et al., 2006). In Alzheimer’s
and Parkinson’s disease patients with impaired cognitive function, the expression of
muscarinic receptors was found to be decreased in the brain (Rodriguez-Puertas et
al., 1997; Araki et al., 2000).

Statins, hydroxymethylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, were
normally recognized to lower plasma cholesterol. In addition to lowering cholesterol,
statins have gradually been used to reduce the risk of heart attack, cerebral ischemia,
and have been demonstrated to exert potential beneficial effects in different
neurological diseases (Wang et al., 2007; Keener & Sanossian, 2008; van der Most et
al., 2009; Sugawara et al., 2011; Ayer et al., 2013). Although the precise

mechanisms are unclear and contrasting results have been observed (Reiss &
Wirkowski, 2007; Becker et al., 2008), additional studies have found that statins
display important effects on cognitive related neurological diseases such as PD (Wu
et al., 2008; van der Most et al., 2009; Wang et al., 2011; Lee et al., 2013; Xu et al.,
2013). If statins would have a potentially useful impact on impaired memory
regulation in the progression of PD, this presents an interesting challenge. Besides
characterized by typical disturbances of dopaminergic system, PD patients also
display widely unbalances in other systems including cholinergic system (Gubellini
et al., 2004; Lester et al., 2010; Xu et al., 2012). It has been indicated that the
interruption of dopaminergic system may influence the cholinergic system in PD
(Andersson et al., 2010; Lester et al., 2010). Our studies and Selley (Selley, 2005;
Wang et al., 2005) have shown that simvastatin regulated dopaminergic systems
including receptors and transmission in the brain. Also, our study found the alterations
of NMDA and M1/4 receptors in the brains following simvastatin treatment (Wang et
al., 2008; Wang et al., 2009b; Yan et al., 2011). Whether the application of simvastatin
in Parkinsonian rats also influences the expression of M1 receptors raises an interesting
question.

Based on the information above, we propose that simvastatin may reverse the decline
in M1/4 receptors in memory-related regions of the brain in 6-OHDA-induced PD
rats. To test this hypothesis, [3H]pirenzepine binding autoradiography was applied to
verify the reactions of muscarinic receptors M1/4 to 3-week treatment of simvastatin
in the 6-OHDA-induced PD rat model. Besides, we also investigated the impairment
of memory in this PD rat model, as well as the influence of simvastatin on declined

memory in the PD rat model. The current study provides a possible association of
simvastatin treatment with M1/4 receptors in the Parkinsonian rat brain.

Materials & Methods
Animals and drug treatments
Twenty-two Sprague-Dawley rats (male, 230-250 g/rat) were purchased from the
Animal Resources Centre (Perth, Western Australia, Australia) and kept in
specifically environmental conditions as previous description (Li et al., 2010). Rats
were housed for one week to be accustomed to the new environment before
experiments start. The rats were randomly assigned to groups with a total of sixteen
rats for the 6-OHDA lesioned group, among which eight of the rats were
administered with simvastatin (10 mg/kg/day) orally and the rest rats were orally
administrated with saline. One 6-OHDA lesioned rat receiving saline died after
surgery. In the control group, six rats received 0.9% saline for three-week oral
administration as the vehicle control. After three weeks of 6-OHDA lesion, all rats
were sacrificed to examine M1/4 receptor binding. This study was approved by the
local Animal Ethics Committee, and followed the instructions in compliance with the
National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH
Publications No. 80-23) revised 1996 guidelines and National Health and Medical
Research Council (NHMRC) Australian Code of Practice for the Care and Use of
Animals for Scientific Purposes (2004).

6-OHDA lesioned Parkinsonian rats
The 6-OHDA lesioned rat was created as described in Yan’s work (Yan et al., 2011).
Briefly, the rats were anesthetized with 75 mg/kg ketamine and 10 mg/kg xylazine

(Troy laboratories Pty, Ltd., Australia). 4 μl 6-OHDA was diluted in the normal
saline (8 μg/μl in normal saline containing 0.2 mg/ml ascorbic acid, Sigma-Aldrich,
St. Louis, MO) were unilaterally injected into the medial forebrain bundle (0.8
μl/min; at AP −4.4 mm, ML −1.4 mm and DV −7.8 mm, from Bregma (Paxinos &
Watson, 1997). The control group were orally administrated with the 0.9% saline
vehicle, and received the 0.9% saline injection into the MFB. These animal
procedures were conducted according to the protocols set up by the University of
Wollongong, adapted from Howard-Jones (Howard-Jones, 1985).

Morris water maze (MWM)
Three weeks after the 6-OHDA lesion was performed, rats were tested in the MWM
to assess the level of long-term memory. The MWM was described in previous
studies (Andringa et al., 2000; Wisman et al., 2008). Briefly, the pool dimensions
were a diameter of 185 cm and a water depth of 30 cm, and the water temperature
was 21° Celsius. A hard plastic circular cover that fits inside the wall of pool was
used as a protective sheath so that the rats would not scratch the rubber pool material.
Four starting positions were conventionally indicating east, south, west, and north,
which divided the pool into 4 quadrants. A target platform (10 x 10 cm) was placed
midway between the center and the western point. The platform consisted

of transparent plexiglass and was submerged 1.5 cm beneath the surface
of the water. Rats were tested 2 days in succession, with two training
trials conducted in the first day for the learning phase. On the second
day, the test trial was performed to test the long-term memory. The
distance that the rat travelled and the time that the rat took to reach the

platform was recorded by a camera placed 2 meters above the water
maze. Distance and duration was traced and calculated using Ethovision
Color-Pro software (Nldus information Technology, Wageningen, The
Netherlands).

Tyrosine hydroxylase immunohistochemistry staining
After the MWM behavioral test, the rats were used for tyrosine
hydroxylase (TH) staining. TH staining was performed as described in
Yuan’s study (Yuan et al., 2005; Yan et al., 2011). Briefly, distilled
water was used to wash the brain sections for three times (5 min/per
time), and the sections were immerged in citrate buffer for 20 minutes.
1.5% goat serum was used to block the non-specific binding (Vectastain
rabbit IgG ABC kit). The sections were incubated with TH primary
antibody (rabbit

polyclonal

anti-tyrosine hydroxylase, Millipore

Corporation, AB152) overnight at 4 °C. On the following day, the
sections were incubated with the secondary antibody for 60 min
followed by PBS wash. After ABC (Vectastain rabbit IgG ABC kit) and
DAB kits were applied (DAB, Vector SK-4100), the sections were
determined by light microscopy. The TH staining density was detected
by the NIH ImageJ Analysis software.

Histology and [3H]pirenzepine binding autoradiography

CO2 asphyxiation was used to kill the rats. Microscope slides (Polysine™, Menzel
GmbH & Co KG) were mounted with the brain sections cut at 14 μm thickness (Li et
al., 2010; Yan et al., 2011). Rat brain atlas was used to identify standard brain
structures (Paxinos & Watson, 1997). [3H]Pirenzepine autoradiography was
performed to detect the M1/4 receptor binding (Newell, 2007; Wang et al., 2008).
Briefly, brain sections were incubated in HEPES (pH 7.5) for 15 minutes, and then in
the same buffer but adding 10 nM [3H]pirenzipine (specific activity 86 Ci/mmol;
Perkin Elmer, Norwalk, CT) for 90 minutes. Nonspecific binding was identified with
[3H]pirenzepine in the presence of 10 μM atropine.

Quantification and Statistical Analysis
Beta Imager (BioSpace, Paris, France) was applied to quantify the M1/4 receptor
binding sites as described in our previous studies (Wang et al., 2009b; Yan et al.,
2011). Briefly, brain sections were put in the chamber of Beta Imager followed by
3.5 h scanning. By quantifying the _-particles emitting from the brain sections, the
levels of radioactivity in the tissue were directly determined; while the Beta Vision
Plus program (BioSpace) was used to measure the activities in the interested regions.
The radioligand binding signal was expressed in counts per minute per square
millimeter (cpm/mm2). The radioligand binding signals was converted to nCi/mg
tissue equivalents. Three to five adjacent brain sections were used to quantify the
average density of M1/4 receptor by measuring [3H]pirenzepine binding in various
brain regions. Data were expressed as the mean ± SEM. [3H]Pirenzepine binding
densities for each brain region, and the behavioral data from the MWM were
analysed using a one-way ANOVA followed by a post hoc Dunnett-T test with the
SPSS 15.0 program (Chicago, IL). A Student’s t-test was employed to analyze the

data from the TH immunohistochemistry staining in Cpu. P values of less than 0.05
were regarded as statistically significant.

Results
TH immunostaining in the striatum
In the Striatum: TH immunoreactivity showed that the lesion by 6-OHDA into the
MFB induced an extent nigrostriatal denervation in the striatum (Fig. 1). Fig. 1B
showed a large absence of TH immunoreactive fibers, and the average density of TH
immunoreactivity was expressed as a mean percentage ± S.E.M. The density of THpositive fibers in the lesioned side was reduced around 80% when compared to the
controls (Student t-test: t=18.551, *** p< 0.001, Fig. 1C). In the 6-OHDA lesioned
rat, the TH density in the intact side of striatum was the same as that of control group
(Fig. 1A).

Effects of 6-OHDA lesion and simvastatin treatment on long-term memory
One-way ANOVA demonstrated that there was a significant effect of drug treatment
on the total distance traveled in the MWM (F[2,18] =4.340, p=0.029, Fig. 2A).
Compared to the controls, 6-OHDA caused a significant increase in the total distance
(235% of controls, p<0.05) (Fig. 2A). When compared to the 6-OHDA treated group,
simvastatin significantly prevented this increase in the total distance (41.4% of 6
OHDA group, p<0.05). In addition, one-way ANOVA demonstrated that there was a
significant effect of drug treatment on the ratio of the duration in the west arena to
the total duration (F[2,18] =4.353, p=0.029). A post hoc test indicated that 6-OHDAlesion PD rats showed a significant decrease (27%, p<0.05) in the ratio of the
duration in the west arena to the total duration compared to controls (Fig. 2B). In

comparison to the 6-OHDA-lesion PD rats, simvastatin oral administration
significantly prevented this behavioral deficit in which simvastatin treated PD-rats
had a significantly longer duration in the west arena (36%, p<0.05, Fig. 2B).

Effects of 6-OHDA lesion and simvastatin treatment on [3H]pirenzepine
bindingin the brain regions
[3H]pirenzepine binding sites can be found in most examined areas (Fig. 3). One way
ANOVA revealed significant changes in [3H]pirenzepine binding sites in some
examined brain regions such as hippocampus, the medial amygdala, the posteromedial
cortical amygdale, and the piriform cortex among the 6-OHDA induced PD rats.
Specifically, a Tukey post-hoc analysis showed that [3H]pirenzepine binding in 6OHDA-lesioned rats was profoundly reduced in the hippocampus (9.34%, p<0.01), the
medial amygdala (11.91%, p<0.01), the posteromedial cortical amygdala (12%, p<0.05)
and the piriform cortex (13.60%, p<0.01) compared to the controls (Figs 4 and 5).
However, after three-weeks of administration of simvastatin, the down-regulation of
[3H]pirenzepine binding sites in these examined regions were reversed. Specifically,
simvastatin significantly increased the [3H]pirenzepine binding density in the
hippocampus (11.4%, p<0.01), the medial amygdala (11.38%, p<0.05), the
posteromedial cortical amygdala (12.45%, p=0.064) and the piriform cortex (15.23%,
p<0.001) in comparison to the 6-OHDA MFB lesioned PD rats (Figs 4 and 5).
However, compared to the controls, no significant changes in [3H]pirenzepine binding
were observed in the substantia nigra of the 6-OHDA and simvastatin treated group. In
the caudate putamen (11.07%, p=0.001), [3H]pirenzepine binding was significantly
increased in the simvastatin treated group in comparison to the 6-OHDA and control
groups.

Correlations between duration in west arena of MWM and [3H]pirenzepine
binding density
A moderate positive correlation was observed between the [3H]pirenzepine binding
density in the hippocampus and the duration in the west arena of the water maze
(r=0.491 Pearson’s correlation, p=0.024) in the MWM test (Fig 6A). There were also
significant correlations between the [3H]pirenzepine binding density in the medial
amygdala (r=0.636, p=0.002) with the duration in the west arena of the water maze
(Fig 6B) in the MWM test. However, no significant correlation was observed
between [3H]pirenzepine binding density in the posteromedial cortical amygdala
(r=0.148, p=0.520) or the piriform cortex (r=0.315, p=0.164) and the duration in the
west arena of the MWM.

Discussion
The current study was to explore the changes of [3H]pirenzepine binding density in
6-OHDA lesioned rat brain regions and its association with memory activity after
chronic treatment of simvastatin. Although [3H]pirenzepine possess the higher
concentration, [3H]pirenzepine binds largely to the M1 receptor subtype (Dean et al.,
1999). The present study used 10 nM [3H]pirenzepine, a concentration that was
reported to label approximately 65% of M1 receptors and 18.5% of M4 receptors
(Flynn & Mash, 1993). The current study showed that compared with control group,
the 6-OHDA lesion significantly decreased M1/4 receptor binding in some brain
areas such as the hippocampus, the medial amygdala, the posteromedial cortical
amygdala and the piriform cortex.

In this study, the profoundly reduced TH immunostaining in the striatum of the 6OHDA-lesioned side indicated a complete nerve terminal denervation and successful
6-OHDA induced PD rat model establishment. In the MWM, 6-OHDA lesioned rats
travelled a longer distance and used more time to reach to the target platform
compared to the controls (Fig 2), reflecting the effects of the 6-OHDA lesions, which
induce a decline in long-term memory. Our result is similar to other studies, which
indicated that 6-OHDA or MPTP lesioned PD rodents showed severely impaired
long-term memory activity (Da Cunha et al., 2002; Yang et al., 2004). Clinical
studies showed that before the motor feature deficits showed up, PD patients usually
present nonmotor dysfunctions, especially, the neuropsychiatric dysfunctions, among
which memory impairment is a typically characteristic; in this case, the prevalence
rates were up to 67% in the PD population (Emre et al., 2007). For example, in some
cross-sectional clinical cohort studies, it has been shown that PD patients exhibited
memory deterioration in the early stage and gradually developed progressive
memory decline; while this memory impairment was improved by different medical
interventions (Uc et al., 2009; Wang et al., 2009a; Caviness et al., 2011), the precise
mechanisms are not yet clear. Therefore, it is urgently to investigate the possible
mechanisms on the memory impairment in PD; this study directly implies this
cognitive profile in clinical PD patients.

Our study showed that a 6-OHDA lesion in the MFB induced a reduction of M1/4
receptor binding in the observed brain regions (Figs 4 and 5). This finding is
consistent with other studies demonstrating that M1/4 receptors were decreased in
the brain following 6-OHDA induced dopaminergic depletion (Joyce, 1991a; b). The
precise reasons for the reduced M1/4 receptor following a 6-OHDA lesion are not yet

known. However, it has been documented that dopaminergic denervation in the
striatal pathway resulted in hyperactivity of the cholinergic systems (Muma et al.,
2001; Zhang et al., 2008). Therefore, we hypothesize that the possible mechanisms
for the reduced M1/4 receptors involved in our study is due to enhanced striatal
cholinergic neuron firing following dopamine denervation in the nigrostriatal
pathway; however, we cannot exclude the possibility that the reduced M1/4 receptors
in the observed brain areas may reflect the receptor hypo-innervations. However, the
precisemechanisms behind it remain to be determined.

It has been well documented that the changes of M1/4 receptors in the some brain
regions are closely correlated with the memory activity. A recent study by
Anagnostaras et al. indicated that through Olton win-shift radial arm maze and
morris water maze studies, M1 receptor knockout mice showed dramatic
forgetfulness and impaired working and contextual memory, implying that the
function of the M1 receptor directly contributes to memory processing (Anagnostaras
et al., 2003). By inhibiting M1 receptors using its antagonist pirenzipine, the longterm potentiation (LTP) induction that serves as a cellular mechanism for memory
was abolished, strongly suggesting that M1 receptors mediate memory and learning
function (Doralp & Leung, 2008). Although some early studies showed no
significant decrease in M1 receptor expression in the brains of declined memory
related disorders (Young & Penney, 1994), more recent studies showed that M1
receptor levels were significantly declined in some important brain regions, such as
the cortex and the hippocampus, among the many memory impairment related
disorders (Parasi et al., 2007). Further, the declined memory in aged rats can be
improved by elevating the expression of M1 receptors in memory related brain

regions, such as the hippocampus and the cortex (Hu et al., 2005; Hu et al., 2008).
This study showed that a profound decrease in the M1/4 receptor binding was
observed in the hippocampus, the medial amygdala, the posteromedial cortical, and
the piriform cortex of the 6-OHDA lesioned side. This robust decrease of M1/4
receptor binding in the hippocampus and medial amygdala, of 6-OHDA lesioned rats
was found to have significant positive correlations with the duration in the west arena
of the water maze in the MWM test (Figs 6A and 6B). These findings strongly
suggest that the M1/4 receptor hypofunction in the hippocampus and medial
amygdale may explain the declined memory in the PD rats. This hypothesis is
supported by the fact that the changes in the M1/4 receptors in the examined regions
directly regulate the memory behaviors.

Similar to previous reports (Rezvani et al., 2008), 6-OHDA lesioned rats in the
current study showed deficits in long-term memory as indicated by the longer total
distance travelled to reach the platform and the shorter duration in the west arena of
the water maze. It is important that simvastatin treatment significantly increased the
reduced total distance travelled in the MWM and the duration of the 6-OHDAinduced PD rats in the west arena of the water maze (Fig 2), demonstrating the
ability of simvastatin to produce a profound improvement in impaired memory
effects in the 6-OHDA lesioned PD rats. Consistent with our results, through
behavioral tests, Chopp’s team and others also found that simvastatin substantially
improved deficit spatial learning and memory in an established mouse model of AD
and rats subjected to traumatic brain injury (Li et al., 2006; Lu et al., 2007; Wu et al.,
2008). An increasing number of clinical studies have indicated close association
between statins and improvement in declined memory in the elderly population. In a

follow-up cohort investigation, Solomon et al. demonstrated that subjects with
pronounced impairment in episodic memory benefited from statins usage, implying
that statins exert useful impacts on memory deficits in the elderly (Solomon et al.,
2009). Several prospective studies showed that poorer memory performance was
significantly ameliorated in Parkinson’s disease following statin therapy (Wahner et
al., 2008; Mutez et al., 2009). However, the means by which statins affect memory
and several possible mechanisms underlying memory regulation are under
exploration. The current study showed that the reduced [3H]pirenzepine binding sites
in the observed brain regions was reversed after chronic treatment of simvastatin,
which is consistent with our previous study showing an increase of M1/4 receptors in
the rat brain following simvastatin treatment (Wang et al., 2008). This result
indicated that the increase of M1/4 receptor binding in the hippocampus and the
medial amygdala of 6-OHDA lesioned rats after chronic treatment of simvastatin was
identified to have significant positive correlations with the duration in the west arena
of the MWM (Fig 6). This finding implies that simvastatin ameliorated the declined
memory in 6-OHDA lesioned rats via M1/4 receptor modulation.

In addition to the in vivo and in vitro studies, recent clinical studies indicated that
some types of statins may be associated with a reduction in PD risk. A populationbased study by Lee et al., indicated that the continuation of lipophilic statin, such as
atorvastatin and simvastatin, therapy was associated with a decreased incidence of
PD (Lee et al., 2013). During 12 years of follow-up (1994-2006) study, Gao et al.,
found that the regular statin medication was correlated to a reduction in PD risk (Gao
et al., 2012). Similar clinical meta analysis and review on the association of statin
therapy with the decreased risk of PD was also obtained in other studies (van der

Most et al., 2009; Dolga et al., 2011; Noyce et al., 2012). Taken together, clinical
and epidemiological investigations provided strong evidence that statin therapy may
be used to slow down the progression of PD patients. In conclusion, the current study
provides the solid evidence indicating the influence of simvastatin on M1/4 receptor
binding in the PD rat brain. It also reveals possible M1/4 receptor modulation effects,
which indicates an interesting and potential paradigm to ameliorate memory deficits.
According to our results, we reasonably speculate that the improvement in long-term
memory performance due to simvastatin administration in 6-OHDA-induced rats is,
at least partially, associated with a reversal of the declined M1/4 receptor density.
This work presents a possible mechanism for the amelioration of memory deficits in
PD by simvastatin, suggesting that it is mediated by M1/4 receptor modulation.
Although the rat brain resembles the human brain to a certain degree, it does not
mean we can directly translate the results from animal data to humans. However, this
current animal study could provide pre-clinical evidence for clinical studies on PD. A
better understanding of the roles and correlations between statins and dopaminergic
and muscarinic systems may provide new perspectives on the role of statins in
regulating neurodegenerative diseases such as PD and AD.
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Figure legends

Fig 1. Effects of 6-OHDA lesion on TH immunohistochemistry staining in the
caudate putamen. Photo (A) represents the striatum in the control group in which the
TH immunoreactive fibers are the same as in the intact side. The right side of the
photo (B) shows the dopamine-depleted striatum side, which is characterized by a
significant lack of TH immunoreactive fibers, while the left side is the intact side.
(C) represents the average density of TH-positive fibers for the lesioned side and the
contralateral (intact) side (Student’s t-test: t= 18.551, ***P < 0.001).

Fig 2. Effects of simvastatin on the long-term memory activity of control, 6-OHDAlesioned, and 6-OHDA-lesioned with simvastatin administration rats in the MWM
test. The graph shows the total distance travelled and the ratio of the duration in the
west arena to the total duration in the MWM. The parameters are expressed as the
total distance (A) and the percentage of time spent in the west zone to the total time
(B) in the MWM. (A) represents the mean ±SEM, n=6-8. *p<0.05, 6-OHDA group
versus control group; **p < 0.01, 6-OHDA + saline group versus 6-OHDA +
simvastatin group. (B) represents the mean ±SEM, n=6-8. *p<0.05, 6-OHDA group
versus control group; ＃ p < 0.05, 6-OHDA + saline group versus 6-OHDA +
simvastatin group.

Fig 3 The maps of A, B and C are adapted from a rat brain atlas (Paxinos & Watson,
1997) indicating the levels where the [3H]pirenzepine binding density was measured.
Autoradiographs (D, E, F) and (D', E', F') depict the expression of [3H]pirenzepine

binding and non-specific [3H]pirenzepine binding, respectively, at different rostrocaudal coronal levels of the rat brain.

Fig 4 Typical autoradiographs depict the expression of M1 receptors in the
hippocampus (Hippo) and amygdale (Amy) among the control rats, the 6-OHDA
lesioned rats and the 6-OHDA lesioned rats with simvastatin treatment.

Fig 5 The effects of chronic simvastatin treatment on [3H]pirenzepine binding in the
different groups of rat brain regions. Note: Units of measurement are in nCi/mg
tissue. Data are represented as the mean ± SEM. Asterisks indicate significant
differences from the control group (saline), and the cross indicates significant
differences between the 6-OHDA rats and the 6-OHDA with simvastatin treated rats
(*p<0.05; †p<0.05; ††p<0.01; one-way ANOVA followed by Tukey’s test).

Fig 6 Correlations between the duration in the west arena of the MWM and
[3H]pirenzipine binding density in brain regions. A significant positive correlation
was identified between the [3H]pirenzepine binding density in the hippocampus
(r=0.491 Pearson’s correlation, p=0.024, Fig A), amygdala (r=0.636, p=0.002, Fig
B), and the duration in the west arena of the MWM test. However, no significant
correlation was observed between [3H]pirenzepine binding density in the
posteromedial cortical amygdala (r=0.148, p=0.520), the piriform cortex (r=0.315,
p=0.164), and the duration in the west arena of the MWM.

Fig. 5

Fig.6

